 This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 BUILD 3 NCT00391443 will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis IPF. 